Aqualung Therapeutics Concludes ALT-100 Antibody Dosing in Its P1a Study with no Reported SAEs. Will Engage FDA for Clearance of the P2a PUERTA Study in ModerateSevere Acute Respiratory Distress Syndrome Patients
Slightly above 67% of Aridis Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Aridis Pharmaceuticals pink sheet suggests that many investors are alarmed at this time. Aridis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Aridis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Aridis Pharmaceuticals pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Aridis daily returns and investor perception about the current price of Aridis Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Aridis |
Aqualung has selected Novotech as their CRO partner to conduct the P2a PUERTA study in moderatesevere ARDS subjects.Expected screening for enrolled subjects to begin AprilMay 2023.Aqualung Submitting an end of P1 meeting data packet to the FDA in February based on preliminary results of the P1a Healthy Human Volunteer study.TUCSON, AZ ACESSWIRE January 31, 2023 Aqualung Therapeutics, an early stage immunotherapeutics company with a
Read at finance.yahoo.com
![]() |
Aridis Pharmaceuticals Fundamental Analysis
We analyze Aridis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aridis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aridis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Aridis Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Aridis Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aridis Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aridis Pharmaceuticals Related Equities
KOD | Kodiak Sciences | 2.49 | ||||
HOTH | Hoth Therapeutics | 1.10 | ||||
RVPH | Reviva Pharmaceuticals | 0.70 | ||||
ABVC | ABVC Biopharma | 1.23 | ||||
REVB | Revelation Biosciences | 1.67 | ||||
DRMA | Dermata Therapeutics | 1.72 | ||||
EYEN | Eyenovia | 1.74 | ||||
UNCY | Unicycive Therapeutics | 1.79 | ||||
CGTX | Cognition Therapeutics | 2.17 | ||||
VRAX | Virax Biolabs | 2.34 | ||||
AKTX | Akari Therapeutics | 3.33 | ||||
ZVSA | ZyVersa Therapeutics | 3.42 | ||||
RVPHW | Reviva Pharmaceuticals | 7.14 | ||||
ATXI | Avenue Therapeutics | 12.00 | ||||
RNAZ | Transcode Therapeutics | 21.43 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |